| Ovarian Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.94 |
| Cancer |
0 |
0.91 |
| Breast Cancer |
0 |
0.81 |
| Endometrial Cancer |
0 |
0.99 |
| Antineoplastic Drug |
0 |
0.72 |
| Targeted Cancer Therapy |
0 |
0.72 |
| Genomic Medicine |
0 |
0.61 |
| Toxicology |
0 |
0.61 |
| Tumor |
0 |
0.16 |
| California |
0 |
0.12 |
| Clinical Research |
0 |
0.12 |
| Humanized Monoclonal Antibody |
0 |
0.12 |
| Hysterectomy |
0 |
0.12 |
| Intravenous |
0 |
0.12 |
| Platinum |
0 |
0.12 |
| Refractory |
0 |
0.12 |
| Arizona |
0 |
0.08 |
| BRCA |
0 |
0.08 |
| Chemotherapy |
0 |
0.08 |
| Illinois |
0 |
0.08 |
| Texas |
0 |
0.08 |
| Angiogenesis Inhibitors |
0 |
0.06 |
| Antigens |
0 |
0.04 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.04 |
| Breast |
0 |
0.04 |
| Colorado |
0 |
0.04 |
| Europe |
0 |
0.04 |
| Fallopian Tube |
0 |
0.04 |
| Genetics |
0 |
0.04 |
| HIV Infection |
0 |
0.04 |
| Minnesota |
0 |
0.04 |
| Missouri |
0 |
0.04 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.04 |
| Ovary |
0 |
0.04 |
| Peritoneum |
0 |
0.04 |
| Quality of Life |
0 |
0.04 |
| Receptors |
0 |
0.04 |
| Revenue and Practice Management |
0 |
0.04 |
| Salary and Compensation |
0 |
0.04 |
| Uterus |
0 |
0.04 |
| Virginia |
0 |
0.04 |